Trials / Recruiting
RecruitingNCT06412471
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 235 (estimated)
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study includes two parts, part A is for non-squamous NSCLC and part B is for squamous NSCLC.
Detailed description
This study is a study of SSGJ-707 combination therapy in First-line advanced NSCLC Patients. This study includes two parts, part A is for non-squamous NSCLC and part B is for squamous NSCLC. Each part will assess the efficacy and safety of the preset several dose levels of SSGJ-707 in advanced NSCLC Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SSGJ-707 | bispecific antibody |
| DRUG | carboplatin | chemotherapy |
| DRUG | Pemetrexed | chemotherapy |
| DRUG | paclitaxel | chemotherapy |
| DRUG | PD-1/L1 | Immune checkpoint inhibitors |
| DRUG | Paclitaxel-albumin | chemotherapy |
Timeline
- Start date
- 2024-07-26
- Primary completion
- 2025-07-01
- Completion
- 2025-08-01
- First posted
- 2024-05-14
- Last updated
- 2024-07-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06412471. Inclusion in this directory is not an endorsement.